EU/3/01/068

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in December 2008 on request of the Sponsor.

On 19 December 2001, orphan designation (EU/3/01/068) was granted by the European Commission to Kendle International Limited, United Kingdom, for thalidomide for the treatment of multiple myeloma.

Key facts

Active substance
Thalidomide
Disease / condition
Treatment of multiple myeloma
Date of first decision
19/12/2001
Outcome
Withdrawn
EU designation number
EU/3/01/068

Sponsor's contact details

Kendle International Ltd
Angel House
24 Station Road
Ely, Cambs CB7 4BS
United Kingdom
Telephone: +44 13 53 66 97 89
Telefax: +44 13 53 66 84 73
E-mail: info.ely@kendle.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating